ArticleCNS neuroscience & therapeutics2026
Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod.CNS neuroscience & therapeutics · 2026Article
- Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundEfgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for generalized Myasthenia Gravis (gMG), but predictors of early response are unclear. Using minimal symptom expression (MSE) as the therapeutic target, we developed and externally validated a clinical model to predict early MSE response after starting efgartigimod. This efgartigimod-tailored model estimates the baseline probability of achieving early MSE and may assist in individualized treatment selection at therapy initiation.
methodsWe retrospectively analyzed 118 adults with gMG treated at five tertiary centers in China (efgartigimod 10 mg/kg IV weekly ×4). MSE was defined as Myasthenia Gravis-Activities of Daily Living (MG-ADL) ≤ 1 sustained ≥ 4 weeks; early MSE response was achievement within 4 weeks of initiation. Patients were split into a derivation cohort (n = 64; three centers) and an external validation cohort (n = 54; two centers). Candidate predictors included demographics, baseline severity, and laboratory indices. Variables associated with early MSE in univariable analyses entered multivariable logistic regression to construct a nomogram. Discrimination (AUC-ROC), calibration (curves and Spiegelhalter Z-test), and clinical utility (decision curve analysis, DCA) were assessed, with bootstrap internal validation.
resultsEarly MSE response occurred in 26/64 derivation and 22/54 validation patients. Lower bulbar MG-ADL (OR 0.633, p = 0.040), higher FVC% (OR 1.042, p = 0.048), and lower IgG (OR 0.795, p = 0.036) independently predicted early MSE response. The nomogram showed strong discrimination-derivation AUC 0.869 (95% CI 0.797-0.941), bootstrap AUC 0.880 (0.806-0.954), and external AUC 0.839 (0.760-0.919)-and good calibration (Spiegelhalter Z: 1.03, p = 0.303; 0.94, p = 0.347; 1.17, p = 0.242). DCA indicated net benefit across thresholds 0.05-0.82, with validation curves mirroring derivation.
conclusionsA three-factor nomogram (bulbar MG-ADL, FVC%, and serum IgG) provides an efgartigimod-specific baseline estimate of early sustained-MSE response probability, which may help neurologists select appropriate candidates, counsel expected benefit, and tailor follow-up intensity or alternative escalation strategies. TRAIL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2500101971).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.